Lifecore Biomedical Stock Fundamentals
| LFCR Stock | 5.91 0.15 2.48% |
Lifecore Biomedical fundamentals help investors to digest information that contributes to Lifecore Biomedical's financial success or failures. It also enables traders to predict the movement of Lifecore Stock. The fundamental analysis module provides a way to measure Lifecore Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lifecore Biomedical stock.
At this time, Lifecore Biomedical's Interest Expense is relatively stable compared to the past year. As of 06/07/2024, Gross Profit is likely to grow to about 49.7 M, while Total Revenue is likely to drop slightly above 98.1 M. Lifecore | Select Account or Indicator |
Lifecore Biomedical Company Return On Asset Analysis
Lifecore Biomedical's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lifecore Biomedical Return On Asset | -0.0467 |
Most of Lifecore Biomedical's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lifecore Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Lifecore Total Assets
Total Assets |
|
Based on the latest financial disclosure, Lifecore Biomedical has a Return On Asset of -0.0467. This is 99.47% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The return on asset for all United States stocks is 66.64% lower than that of the firm.
Lifecore Biomedical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lifecore Biomedical's current stock value. Our valuation model uses many indicators to compare Lifecore Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lifecore Biomedical competition to find correlations between indicators driving Lifecore Biomedical's intrinsic value. More Info.Lifecore Biomedical is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . At this time, Lifecore Biomedical's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lifecore Biomedical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Lifecore Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lifecore Biomedical's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lifecore Biomedical could also be used in its relative valuation, which is a method of valuing Lifecore Biomedical by comparing valuation metrics of similar companies.Lifecore Biomedical is currently under evaluation in return on asset category among its peers.
Lifecore Biomedical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lifecore Biomedical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lifecore Biomedical's managers, analysts, and investors.Environmental | Governance | Social |
Lifecore Fundamentals
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.0467 | ||||
| Profit Margin | (0.96) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 376.76 M | ||||
| Shares Outstanding | 30.55 M | ||||
| Shares Owned By Insiders | 6.24 % | ||||
| Shares Owned By Institutions | 75.76 % | ||||
| Number Of Shares Shorted | 2.06 M | ||||
| Price To Book | 1.57 X | ||||
| Price To Sales | 1.79 X | ||||
| Revenue | 103.27 M | ||||
| Gross Profit | 27.29 M | ||||
| EBITDA | (11.12 M) | ||||
| Net Income | (102.19 M) | ||||
| Total Debt | 112.74 M | ||||
| Book Value Per Share | (0.14) X | ||||
| Cash Flow From Operations | (34.46 M) | ||||
| Short Ratio | 14.68 X | ||||
| Earnings Per Share | (2.14) X | ||||
| Price To Earnings To Growth | 3.51 X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 459 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 179 M | ||||
| Total Asset | 255.15 M | ||||
| Retained Earnings | (176.22 M) | ||||
| Working Capital | 60.48 M | ||||
| Net Asset | 255.15 M |
About Lifecore Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4.1 M | 4.3 M | |
| Total Revenue | 103.3 M | 98.1 M | |
| Cost Of Revenue | 76 M | 72.2 M | |
| Stock Based Compensation To Revenue | 0.01 | 0.01 | |
| Sales General And Administrative To Revenue | 0.12 | 0.12 | |
| Research And Ddevelopement To Revenue | 0.02 | 0.02 | |
| Capex To Revenue | (0.01) | (0.01) | |
| Revenue Per Share | 10.08 | 9.16 | |
| Ebit Per Revenue | 0.01 | 0.01 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.